Patient-Centered Outcomes of Deep Brain Stimulation in Parkinson’s Disease. (P1.174)

OBJECTIVE: To determine long-term patient-centered outcomes of bilateral STN DBS in PD, emphasizing satisfaction, quality-of-life and disability. BACKGROUND: STN DBS is effective for motor symptoms of PD but long-term patient-centered outcomes are lacking. DESIGN/METHODS: We developed a survey to query satisfaction in patients >5 years post-DBS, questioning expectations, satisfaction, willingness to hypothetically undergo DBS again, timing of DBS, and confidence in recommending DBS. Patients used scores from 0-10, whereby 0 represented the most ‘positive’ answer. Pre-operative PDQ-39 (quality-of-life, lower score better), UPDRS-II (disability, lower score better), S&E (disability, higher score better) scales were repeated at time of survey. We will report on 100 consecutive patients in this ongoing study. Current data were analyzed using simple comparison. Regression analyses will be used with the future larger data set. RESULTS: 11 patients (mean 9.7±2.7 years post-DBS) completed this ongoing study thus far. Satisfaction was high with median score (range) of 0/10 (0-5) at 1 year, and 1/10 (0-5) at time of survey. Expectation was also high with median score of 3/10 (0-10), but satisfaction still exceeded expectation by 18.18[percnt] after 1 yr and 12.40[percnt] at time of survey. Patients endorsed their decision to undergo DBS, score 0/10, (0-2), would proceed with surgery again, 0/10 (0-4), would have preferred DBS earlier, 2/10 (0-10) and would recommend DBS to others, 0/10 (0-2). Median (range) PDQ-39 scores were 34.24 (22.66-61.67) pre-operatively and 25.11 (12.66-64.38) at time of survey. UPDRS-II-OFF/ON scores were 23/9 (13-32/2-15) pre-operatively and 22/14 (20-27/10-17) at time of survey. S&E-OFF/ON scores were 60[percnt]/90[percnt] (40-90[percnt]/80-100[percnt]) pre-operatively and 50[percnt]/60[percnt] (25-90[percnt]/30-90[percnt]) at time of survey. CONCLUSION: Preliminary results demonstrate that satisfaction with DBS is maintained 9.7±2.7 years after surgery. In general, patients would choose to have surgery again, at an earlier time, and recommend DBS to others. Quality-of-life was maintained as well despite increasing disability. Disclosure: Dr. Karl has nothing to disclose. Dr. Ouyang has nothing to disclose. Dr. Verhagen has received personal compensation for activities with Medtronic Inc., St. Jude Medical, and Depomed as a consultant. Dr. Verhagen has received research support from Medtronic Inc., Adamas Pharmaceuticals, Avanir Pharmaceuticals, US WorldMeds